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Abstract.  Cytotactin is an extracellular matrix protein 
that is found in a restricted distribution and is related 
to developmental patterning at a number of neural and 
non-neural sites.  It has been shown to bind specifically 
to other extracellular matrix components including a 
chondroitin sulfate proteoglycan (cytotactin-binding 
[CTB]  proteoglycan) and fibronectin. Cell binding ex- 
periments have revealed that cytotactin interacts with 
neurons and fibroblasts.  When isolated from brain, 
both cytotactin and CTB proteoglycan contain the 
HNK-1  carbohydrate epitope. Here, specific antibodies 
prepared against highly purified cytotactin and CTB 
proteoglycan were used to correlate the biochemical 
alterations and modes of binding of these proteins with 
their differential tissue expression as a function of time 
and place during chicken embryo development. It was 
found that, during neural development, both the levels 
of expression of cytotactin and C~B proteoglycan and 
of the molecular forms of each molecule varied, fol- 
lowing different time courses. In addition, a novel Mr 
250,000  form of cytotactin was detected that contained 
chondroitin sulfate. The intermolecular binding of 
cytotactin and CTB proteoglycan and the binding of 
cytotactin to fibroblasts were characterized further and 
found to be inhibited by EDTA, consistent with a de- 
pendence on divalent cations.  Unlike the molecules 
from neural tissue, cytotactin and CTB proteoglycan 
isolated from non-neural tissues such as fibroblasts 
lacked the HNK-1 epitope. Nevertheless, the inter- 
molecular and cellular binding activities of 
cytotactin isolated from fibroblast culture medium 
were comparable to those of the molecule isolated 
from brain,  suggesting that the HNK-1  epitope is not 
directly involved in binding. Binding experiments in- 
volving enzymatically altered molecules that lack 
chondroitin sulfate suggested that this glycosaminogly- 
can is also not directly involved in binding. 
Although they clearly formed a binding couple, the 
spatial distributions of cytotactin and CTB proteogly- 
can in the embryo were not always coincident. They 
were similar in tissue sections from the cerebellum, 
gizzard, and vascular smooth muscle. In contrast, 
CTB proteoglycan was present in cardiac muscle 
where no cytotactin is present, and it was seen in car- 
tilage throughout development unlike cytotactin, which 
was present only in immature chondrocytes. Cell cul- 
ture experiments were consistent with the previous 
conclusion that cytotactin was specifically synthesized 
by glia, whereas C~B proteoglycan was specifically 
synthesized by neurons. Both molecules were found ei- 
ther associated with the cell surface or in an intracel- 
lular, perinuclear pattern. These observations are in 
accord with the idea that binding of central glia to 
neurons occurs in part through the cytotactin-CTB 
proteoglycan couple. The combined results of this 
study support the hypothesis that structural modula- 
tions and dynamic interactions among extracellular 
matrix components contribute to the control of cell be- 
havior during development. 
M 
ORPHOGENESIS results from the coordinate expres- 
sion of various cellular primary processes, among 
which cell adhesion and migration play  pivotal 
roles at certain stages of development.  Specific  adhesion 
molecules are important  to  an understanding  of the reg- 
ulation of cell motion and adhesion  that leads to pattern 
formation (11). Such molecules include cell-cell adhesion 
molecules, or CAMs ~ (12), as well as extracellular matrix 
1. Abbreviations used in this paper: CAMs,  cell-cell adhesion molecules; 
CTB proteoglycan,  cytotactin-binding  proteoglycan;  RGD, Arg-Gly-Asp. 
proteins  (36, 39) including various cell-substrate adhesion 
molecules. 
We have previously identified an extracellular matrix pro- 
tein, cytotactin, that has an unusual site-restricted  distribu- 
tion  during  embryogenesis  (8),  and  is  involved  in  neu- 
ron-glia interaction  (17). When isolated  from embryonic 
brain,  cytotactin  appears  as multiple polypeptides  of Mr 
220,000,  200,000,  and  190,000, all  of which express  the 
HNK-I carbohydrate antigenic determinant (17). Polyclonal 
antibodies recognizing these components in extracts of em- 
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bearing polypeptides of Mr 160,000 and 180,000 in extracts 
of adult brain; as shown by one-dimensional peptide maps, 
these components were related to each other but not to the 
three components of cytotactin (17). Further analysis led to 
the finding that a chondroitin sulfate proteoglycan that co- 
purifies with cytotactin binds to  it (20).  The Mr 280,000 
core protein of this proteoglycan isolated from embryonic 
brain tissue carried the HNK-1 determinant. This proteogly- 
can binds specifically to cytotactin and we therefore desig- 
nate  it  CTB  (cytotactin-binding) proteoglycan.  CTB  pro- 
teoglycan inhibits the binding of cytotactin to cells (20);  in 
contrast, fibronectin, which also binds to cytotactin, does not 
inhibit its cell binding. 
The potential importance of cytotactin and CTB proteogly- 
can in affecting cell movement and morphogenesis was sug- 
gested by observations (8) that cytotactin appears in the de- 
veloping embryo in a  succession of cephalocaudal waves. 
This molecule and the CTB proteoglycan exhibit a striking 
asymmetric distribution during somite formation and neural 
crest cell migration that is correlated with the position of 
crest cells in the sclerotome (34).  Functional tests in vitro 
showed that cytotactin and CTB proteoglycan caused cell 
rounding and halted the migration of neural crest cells on 
fibronectin substrates (34),  suggesting that these molecules 
may differentially affect the cell migration known to occur 
on fibronectin (32).  Consistent with this idea, perturbation 
experiments with specific antibodies have shown that cyto- 
tactin is also involved in the control of cell migration in the 
developing cerebellum (7). 
The current study was undertaken to relate the expression 
of cytotactin and CTB proteoglycan at various sites and times 
of development, to determine at which sites they might inter- 
act during histogenesis, and to correlate these findings with 
their biochemical and binding properties. Using highly spe- 
cific antibodies to the purified proteins, we found various 
biochemical changes in the forms and amounts of authentic 
cytotactin and CTB proteoglycan at various sites during de- 
velopment, differentially glycosylated forms of these mole- 
cules, and complex interactions among cytotactin, CTB pro- 
teoglycan,  and  fibronectin that affected their  interactions 
with cells. The results further support the idea that an inter- 
active network of matrix components that are synthesized at 
different times and places and are modulated by binding in- 
teractions may control cell behavior during morphogenesis. 
Materials and Methods 
Purification of  Cytotactin and CTB Proteoglycan 
Both molecules were purified from 95,000 g supernatants of 14-d-old em- 
bryonic brain tissues homogenized in NaCI  (8  g/liter)/KCl (0.3  g/liter)/ 
NaH2PO4  (0.025  g/liter)/KH2PO4  (0.025  g/liter)/NaHCO3  (1  g/liter)/glu- 
cose (2 g/liter)/1  mM phenylmethylsulfonyl fluoride (PMSF; Eastman Ko- 
dak Co., Rochester, NY)/2%  (vol/vol)  trasylol (Mobay Chemical Corp., 
Pittsburgh, PA). The extract from 1,000 brains in 400 ml was incubated for 
3 h at 4~  with 50 ml of DE52 (Whatman Inc., Clifton, NJ). The DE52- 
bound fraction contained ",,90% of the CTB proteoglycan and ,',,25% of the 
cytotactin and was, therefore, used as the source of CTB proteoglycan. After 
washing with PBS (NaCI [8 g/liter]/KCl [0.2 g/liter]/KH2PO4  [0.2 g/liter]/ 
Na2HPO4 [1.15 g/liter]), the DE52 was eluted with 100 ml of 2.7 M NaC1 
in PBS. When the DE52 eluate from 5,000 brains had been collected, it was 
dialyzed versus H20,  lyophilized, and dissolved in 4  M  guanidine-HCl/ 
0.1 M sodium phosphate (pH 7.4) plus 0.6 g/ml CsC1. This solution was cen- 
trifuged in a VTi50 rotor (Beckman Instruments, Inc., Palo Alto, CA) at 
170,000 g for 24 h at 20~  The resulting density gradient was fractionated, 
and those fractions with a density >1.42 g/ml that contained no polypeptides 
that entered a 6 % gel before chondroitinase treatment were pooled, dialyzed 
versus H20, and lyophilized. For the preparation of chondroitinase-treated 
CTB proteoglycan, the sample was then resuspended in PBS and treated 
with 0.5 U of chondroitin ABC lyase (Miles Laboratories Inc., Naperville, 
IL) for 4 h at 37~  This treatment removed ,,092% of the uronic acid from 
CI'B proteoglycan as quantitated by standard methods (1). CTB proteogly- 
can or chondroitinase-treated CTB proteoglycan was then dissolved in 4 M 
guanidine-HCl/0.1 M sodium phosphate (pH 7.4) and further fractionated 
either by  centrifugation  (24  h,  20~  150,000  g)  on  sucrose gradients 
(5-20% sucrose in the same buffer) or by gel filtration on Sephacryl S-500 in 
the same buffer.  In either case, after fractionation,  fractions containing 
purified CTB proteoglycan were identified by gel electrophoresis and Stains- 
all (Eastman Kodak Co.) staining (15), pooled, dialyzed versus H20,  and 
lyophilized. 
The DE52-unbound fraction described above was the source of cytotac- 
tin. This material was incubated for 3 h at 4~  with 50 ml of Sepharose 
CL-2B beads to which 150 mg of 1D8 (a monoclonal antibody specific for 
a  polypeptide epitope in  cytotactin) had  been covalently coupled using 
CNBr (9). The beads were washed with PBS and eluted with 100 ml of 50 
mM diethylamine; the eluate was then neutralized with 10 ml of I M sodium 
phosphate (pH 6.0). When the 1D8 eluate from 5,000 brains had been col- 
lected, it was dialyzed versus H20, lyophilized, and run on a CsCI density 
gradient as described above for CTB proteoglycan. In this case, fractions 
with a density <1.38 g/ml were pooled, dialyzed versus H20, and lyophi- 
lized. The sample was then fmctionated by gel filtration on Sephacryl S-500 
in 4 M guanidine-HCl/0.1 M sodium phosphate (pH 7.4). Both of  these steps 
removed residual CTB proteoglycan, which was found in dense fractions in 
the CsCI gradient fractionation and in lower molecular weight fractions than 
cytotactin during gel filtration. Fractions containing purified cytotactin (k~ 
0.37-0.54)  were identified by SDS gel electrophoresis, pooled, dialyzed 
versus H:O, and lyophilized. 
Purification of CTB Proteoglycan and Cytotactin 
from Fibroblast  Culture Medium 
Fibroblasts were isolated from the body walls of 9- to ll-d-old chicken em- 
bryos, were cultured by standard methods for 2-4 d, and the conditioned 
medium  was collected.  For  the purification of CTB  proteoglycan,  dry 
guanidine-HC1 was added to a final  concentration of 4 M, and CsCI was 
added to 0.6 g/ml. The pH was adjusted to 7.4 with NaOH, and density frac- 
tionation was performed as described above. For the purification of cytotac- 
tin, the fibroblast-conditioned  medium was incubated with monoclonal anti- 
body 1D8 eovalently linked to Sepharose CL-2B, and the eluate was further 
purified on sucrose gradients. Both of these steps were performed as de- 
scribed above. 
Purification of Mr 180,000 Protein 
A mixture of  proteins bearing the carbohydrate epitope recognized by mono- 
clonal antibody HNK-1 was purified from adult chicken brain extracts as 
previously described (17). This material, which contained the Mr 180,000 
and  160,000 polypeptides, was injected into mice. Hybridomas were pre- 
pared, and their culture superuatants were screened by their ability to im- 
munoprecipitate the Mr  180,000 polypeptide. The monoclonal antibodies 
synthesized by two clones identified in this manner were found to im- 
munoprecipitate specifically the Mr 180,000 polypeptide but were not use- 
ful in immunoblotting and in immunohistochemistry. To purify quantities 
of the Mr 180,000 polypeptide sufficient to prepare polyclonal antibodies, 
the same extracts used as a source of cytotactin and CTB proteoglycan were 
incubated with these monoclonal antibodies coupled to Sepharose CL-2B, 
and were washed, eluted, and concentrated as described above in the case 
of cytotactin and monoclonal antibody 1D8. 
Gel Electrophoresis  and Immunoblotting 
SDS gels (25) were run and immunoblotted (37) or stained with Coomassie 
Blue or silver (28) by standard methods. Immunoblots were quantitalexi by 
cutting out appropriate regions of the nitrocellulose and determining the 
amount of bound ~2SI-protein A as previously described (21). 
Preparation of  Antibodies 
Cytotactin, chondroitinase-treated CTB proteoglycan, or the Mr  180,000 
polypeptide was purified as described above, and 50-~g aliquots were in- 
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fied cytotactin and CTB proteoglycan. Cytotactin and chondroitin- 
ase-treated  CTB proteoglycan were prepared as described in the 
Materials  and Methods and resolved  on SDS gels containing  6% 
acrylamide.  Lane 1, 4 Ixg cytotactin;  lane 2, 4 I~g cytotactin treated 
with 0.005 U of chrondroitin ABC lyase for 30 min at 37~  lane 
3, 4  ~tg chondroitinase-treated  CTB proteoglycan; lanes  4 and 6, 
2 gg cytotactin; and lanes 5 and 7, 2 ~tg chondroitinase-treated  C'I'B 
proteoglycan. The detection methods used were Coomassie Blue 
staining (lanes I  and 2), silver staining (lane 3), and immunoblot- 
ting with  anti-cytotactin antibodies  (lanes  4 and 5) or anti-CTB 
proteoglycan antibodies  (lanes  6 and 7). The migration and Mr ￿ 
10  -3 of standard  proteins  are  indicated.  The arrow indicates  the 
position  of the chondroitinase-sensitive  Mr 250,000 component of 
cytotactin. 
jected into rabbits. Atiquots of the cytotactin and CTB proteoglycan used 
for injection are shown in Fig. 1, lanes I and 3. IgG and Fab' fragments (3) 
were prepared from the immune sera. Monoclonal anti-Ng-CAM antibod- 
ies were prepared as previously described (16). 
Preparation of  Extracts 
The indicated cells or tissues were collected, suspended in 5 vol of  PBS/2 % 
(vol/vol) trasylol/l mM PMSE and disrupted using a Polytron homogenizer 
(Brinkmann Instruments Co., Westbury, NY). The homogenates were cen- 
trifuged for 10 min at 10,000 g. The supernamnts were saved, and the pellets 
were resuspended in 0.5% NP-40/PBS and recentrifuged. These superna- 
rants were also saved, and the pellets were resuspended in 8 M guanidine- 
HC1/0.2 M sodium phosphate (pH 7.4) and recentrifuged. Again, the super- 
natants were saved, and all three supernatants were dialyzed versus H20 
before resolution on SDS gels. The first supernatant is referred to as the 
"PBS extract;' the second as the "NP-40 extract" and the third as the "guani- 
dine extract" When extracts were to be chondroitinase-treated, 25-1xl ali- 
quots of the dialyzed extracts were incubated with 0.0t  U  of chondroitin 
ABC lyase for 30 rain at 37~  in the presence of 5  mM EDNA,  5  mM 
N-ethyl maleimide, and 3 mM PMSF. 
Immunohistochemistry 
Paraffin sections were prepared for staining (26). Briefly,  whole embryos 
or dissected organs were frozen in isopentane cooled in liquid nitrogen and 
immediately immersed in methanol at -70~  After 40-70 h, the embryos 
were serially transferred to methanol equilibrated at  -20% 4% and 20~ 
incubating them for at least 3 h at each step. The samples were then im- 
mersed twice in xylene for 15 min and then transferred to a solution of  50% 
Paraplast (Monoject Scientific, St. Louis, MO) in xylene at 45~  for 15 min, 
infiltrated twice with Paraplast in a vacuum oven at 45~  for 10 min, and 
embedded in Paraplast. Sections 10-p.m thick were cut using a model 3010 
microtome (Reichert Scientific Instruments, Buffalo,  NY).  For immuno- 
fluorescent  staining, the deparaffinized  sections were incubated sequentially 
with the primary antibody (1:100 dilution of serum in PBSt5 % nom~ goat 
serum) and fluorescein-conjugated goat anti-rabbit IgG (Cappel Laborato- 
ries, Cochranville, PA), mounted in 90% gycerol/PBS, and observed in a 
Zeiss microscope. Sections to be incubated with anti-CTB proteoglycan an- 
tibodies were first treated with 0.025 U/ml in PBS of  chondroitin ABC lyase 
for  30  min  at  25~  Little  or  no  labeling  was  obtained  without  this 
treatment. 
To determine whether CTB proteoglycan is synthesized by neurons or 
glia, 9-d-old embryonic chicken brain cells were cultured on glass cover- 
slips and fixed as previously described (18). Cells were permeabilized by 
including 0.5% NP-40 in all buffers and were chondroitinase-treated by in- 
cubation with 0.1 U/ml of chondroitin ABC lyase for 1 h at 25~  For im- 
munofluorescent staining with polyclonal rabbit antibodies, samples were 
treated as described above. In double-labeled experiments, samples also 
were incubated sequentially with 100 I.tg/ml of a monoclonal antibody in 
PBS/5%  normal goat serum and rhodamine-conjugated goat anti-mouse 
IgG (Cappel Laboratories). 
Preparation and Use of Covaspheres 
To prepare Covaspheres (Duke Scientific Corp., Palo Alto, CA) for binding 
studies, 50-I.d aliquots of  Covaspberes were incubated with 10 t.tg  of  cytotac- 
tin, CTB proteoglycan, or human fibronectin (New York Blood Center) and 
processed and  stored as  previously described.  Under these conditions, 
100% of the cytotactin or fibronectin became covalently attached to the 
Covaspheres, but only 20% of the CTB proteoglycan bound to the beads. 
In Covasphere to Covasphere binding assays, Covaspheres were soni- 
cated for 20 s in a bath sonicator, and 10-~tl aliquots of Covaspheres were 
mixed in the presence of 0.5 mM CaCI2. After 30-min incubation at 25~ 
the samples were diluted to 20 ml in PBS that had been filtered with a 0.45- 
Ixm filter,  and 0.5 ml-aliquots were analyzed in a Coulter Counter model 
ZBI (Coulter Electronics, Hialeah, FL) with a  100-1xm aperture set at am- 
plification 1/8, aperture current 0.177, and threshold 10-100 (these settings 
should count aggregates of ~40 Covaspheres). In the reported experiments 
where strong aggregation was observed, particle counts were >10,000.  At 
this level of aggregation, <20%  of monomer Covaspheres remain outside 
of aggregates. 
In Covasphere to fibroblast binding assays, cells were prepared by the 
light trypsin method (2), but in the presence of 1 mM CaCI2  instead of 
EDTA.  Cells (1  ￿  106 in  I00  gtl suspension culture medium [No.  330- 
1650; Gibco, Grand Island, NY]/1  mM CaCI2) plus 10-p.l aliquots of soni- 
cated Covaspheres  bearing radioiodinated proteins (50,000 cpm) plus the in- 
dicated other molecules were incubated for 20 min at 25"C, and cells with 
bound Covaspheres were separated from unbound Covaspheres as previ- 
ously described (20).  In a typical experiment, ~5%  of cytotactin-coated 
Covaspheres or fibronectin-coated Covaspheres bound to cells. To confirm 
that the remaining unbound Covaspheres were equally capable of binding 
to cells, in a control experiment, unbound cytotactin-coated Covaspheres 
and fibronectin-coated Covaspheres were each reincubated with a second 
aliquot of cells and found to bind at the 5% level, indicating no depletion 
of binding activity during the initial incubation. 
Results 
Purification of Cytotactin and 
CTB Proteoglycan  from Embryonic Chicken Brain 
and Characterization of Specific Antibodies 
In a previous study  (20),  purified cytotactin  and CTB pro- 
teoglycan were found to bind to each other. To overcome the 
low  levels  of cross-contamination  that  were  observed  in 
cytotactin  and CTB proteoglycan preparations  and that may 
result  from their  mutual  affinity,  more  stringent  schemes 
were devised to yield extremely pure molecules for generat- 
ing  polyclonal  antibodies.  As  described  in  detail  in  the 
Materials  and Methods, the fractionation of the proteoglycan 
took advantage  of its high negative charge and high density. 
The fractionation of cytotactin  took advantage  of the avail- 
ability of a specific monoclonal anti-cytotactin antibody as 
well as of the lower density of the cytotactin  molecule. For 
both CTB proteoglycan and cytotactin,  density fractionation 
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4 M guanidine-HC1 to minimize intermolecular interactions. 
In accord with previous studies (17, 20),  purified cytotac- 
tin preparations contained three major components of Mr 
220,000, 200,000, and 190,000 (Fig. 1, lane 1 ). In addition, 
a  minor component of Mr 250,000  was  detected that was 
sensitive to chondroitinase treatment (compare lane 2 with 
lane 1 ). This component was also recognized on immuno- 
blots by a monoclonal antibody specific for a polypeptide 
epitope in cytotactin, indicating that it is an authentic form 
of the molecule (data not shown). As previously described 
(20),  chondroitinase-treated  CTB  proteoglycan  migrated 
with an  apparent Mr  of 280,000  (lane 3).  Upon  storage, 
components of Mr 250,000,  220,000,  150,000, and  110,000 
routinely appeared in chondroitinase-treated CTB proteogly- 
can preparations, all of which were recognized by specific 
antibodies to the proteoglycan. 
To evaluate the purity of these cytotactin and proteoglycan 
preparations,  polyclonal rabbit  antibodies  were  prepared 
against the isolated molecules. In immunoblotting experi- 
ments, anti-cytotactin antibodies detected purified cytotactin 
(Fig.  1, lane 4) but not chondroitinase-treated CTB proteo- 
glycan (lane 5).  Although the Mr  220,000  component of 
cytotactin was predominant in lane 4, all components of cyto- 
tactin were  recognized by this antibody.  In  contrast,  the 
anti-CTB proteoglycan antibody (prepared against the chon- 
droitinase-treated CTB proteoglycan) detected chondroitin- 
ase-treated  CTB  proteoglycan (lane  7)  but not cytotactin 
(lane 6). Immunoblotting could not be used to analyze intact 
CTB proteoglycan because the molecule transfers poorly to 
nitrocellulose. However, when intact CTB proteoglycan was 
spotted directly onto nitrocellulose,  it was  recognized by 
anti-CTB proteoglycan antibodies and not by anti-cytotactin 
antibodies. 
Molecules with very similar properties to cytotactin have 
been isolated from fibroblasts (13) and cartilage (38)  and 
were shown to appear in electron micrographs as six-armed 
structures  that  Erickson  and  Inglesias  (13) called  hexa- 
brachions. To determine whether cytotactin isolated from the 
brain extracts has a similar morphology, the purified mole- 
cule was rotary shadowed and observed by Dr.  Erickson. 
Hexabrachions that were indistinguishable from those previ- 
ously described (13, 38) were found in the preparations (Fig. 
2). In addition, many four- or five-armed but otherwise simi- 
lar structures were observed. These results indicate that all 
of these  molecules have  similar three-dimensional struc- 
tures and suggest that they are closely related or identical. 
Molecular and Cellular Binding Properties of 
Cytotactin  and Proteoglycan 
In a previous study (20), cytotactin-coated beads were found 
to bind to CTB proteoglycan-coated beads, to fibronectin- 
coated beads, and to cells including neurons and fibroblasts. 
In the present study,  these molecular and cellular binding 
mechanisms  were  investigated  further.  Fibroblasts  were 
found to  be  particularly  useful  to  study  the  binding  of 
cytotactin to  ceils  because  they  bind  substantially  more 
cytotactin-coated beads on a per cell basis than do neurons. 
Binding of cytotactin-coated beads to proteoglycan-coated 
beads or to fibronectin-coated beads was found to be  in- 
hibited by EDTA  (Table I).  Furthermore, the inhibition of 
both intermolecular binding modes was reversed by added 
CaCI2 and not by MgCI2, and the binding was also inhibited 
by EGTA, which is a more specific  chelator of Ca  ++ ions 
(data not shown). These results suggest that these binding 
mechanisms are Ca++-dependent. Both binding mechanisms 
were also inhibited by soluble cytotactin or CTB proteogly- 
can, and by anti-cytotactin Fab' fragments. As expected, only 
the cytotactin-CTB proteoglycan binding mechanism was in- 
hibited by anti-CTB proteoglycan Fab' fragments. Soluble 
fibronectin  inhibited  cytotactin-fibronectin  binding  only 
weakly and had no effect on cytotactin-CTB prote,  oglycan 
binding as previously described (20). Neither binding mech- 
anism was inhibited by a synthetic Arg-Gly-Asp (RGD)-con- 
raining peptide, an amino acid sequence that forms part of 
Table L Effects of Various Molecules on Covasphere-Covasphere Aggregation 
Cytotactin-coated  Covaspheres 
+  CTB proteoglycan-coated 
Covaspheres 
Cytotactin-coated  Covaspheres 
+  fibronectin-coated 
Covaspberes 
Soluble  Superthreshold  Superthreshold 
molecule  particles*  Inhibition  particles*  Inhibition 
%  % 
-  20,200  -  15,100  - 
E DTA  10,600  48  5,700  62 
Anti-cytotactin 
Fab'  900  96  1,700  89 
Anti-proteoglycan 
Fab'  11,900  41  13,800  9 
GRGDS  19,900  1  18,300  (21 )* 
Cytotactin  2,500  88  2,500  83 
CTB proteoglycan  2,300  89  2,800  81 
Fibronectin  20,100  0  12,200  19 
Covasphere-Covasphere binding assays were performed as described in the Materials and Methods. Amounts or concentrations of soluble molecules were: EDTA, 
2 mM; anti-cytotactin or anti-proteoglycan Fab', 20 Ixg; GRGDS (Peninsula Laboratories, Inc., Belmont, CA; Code 9137), 0.5 mg/ml; cytotactin, CTB proteogly- 
can, or fibronectin,  1 txg. 
* Average of duplicate points. In all cases, SD was <1,500 superthreshold particles. Each species of Covasphere, when incubated alone, resulted in <1,000 super- 
threshold particles. 
Promotion. 
The Journal of Cell Biology,  Volume 106,  1988  522 Table 11. Effects of Various Molecules on Covasphere  to Cell Binding 
Cytotactin-coated 
Covaspheres 
Fibronectin-coated 
Covaspheres 
Soluble 
molecule  Bound cpm*  Inhibition  Bound cpm*  Inhibition 
%  % 
--  1,990  --  2,510  -- 
EDTA  510  74  610  76 
Anti-cytotactin 
Fab'  230  88  2,460  2 
Anti-proteoglycan 
Fab'  1,210  39  2,430  3 
GRGDS  1,830  8  1,490  41 
GRGESP  1,830  8  2,250  10 
Cytotactin  1,350  32  1,240  51 
CTB Proteoglycan  570  71  1,020  59 
Fibronectin  1,910  4  1,640  35 
Covasphere to fibroblast binding assays were performed as described in the Materials and Methods. Amounts or concentrations of soluble molecules were: EDTA, 
2 mM; anti-cytotactin or anti-proteoglycan Fab' fragments, 150 I~g; GRGDS or GRGESP  (Peninsula  Laboratories,  Inc.; Codes 9137 and 9135,  respectively), 
0.5 mg/ml; cytotactin,  CTB proteoglycan, or fibronectin,  10 I.tg. 
* Average of duplicate points. In all cases, SD was <200 cpm. Nonspecific binding, as estimated by incubation of fibroblasts with BSA-coated Covaspheres, was 
200 cpm. 
the active site involved in fibronectin binding to cells (22, 
33, 40). 
To evaluate whether there were similarities in the molecu- 
lar mechanisms of binding of these various extracellular pro- 
teins to cells, the binding of cytotactin-coated Covaspheres 
or of fibronectin-coated Covaspheres to fibroblasts was com- 
pared (Table II). Binding of  both kinds of  beads was inhibited 
by EI~A, consistent with the interpretation that the binding 
of cytotactin to cells, like the binding of fibronectin to cells 
(29), is divalent cation-dependent. Soluble CTB proteogly- 
can strongly inhibited cytotactin binding (20) and fibronec- 
tin binding. Soluble cytotactin also inhibited the binding of 
either cytotactin-coated Covaspheres or fibronectin-coated 
Covaspheres to fibroblasts. In contrast, differential effects on 
binding were obtained with other molecules tested. Anti- 
cytotactin FalY fragments and anti-CTB proteoglycan Fab' 
fragments inhibited cytotactin binding but had no effect on 
fibronectin binding. Soluble fibronectin and soluble RGD- 
containing peptide inhibited fibronectin binding but had little 
effect on cytotactin binding;  a  control peptide  containing 
Arg-Gly-Glu had little effect on either cytotactin or fibronec- 
tin binding. 
The observations that both cytotactin and CTB proteogly- 
can contain chondroitin sulfate chains and carbohydrate epi- 
topes recognized by the HNK-1 antibody led us to evaluate 
the role of these carbohydrates in the various binding mecha- 
nisms. Chondroitin sulfate was enzymatically  removed using 
chondroitin ABC lyase. Cytotactin lacking the HNK-1 epi- 
tope (see below) was isolated from fibroblast culture super- 
natants. When the binding of cytotactin-coated Covaspheres 
to CTB proteoglycan-coated Covaspheres or to fibronectin- 
coated Covaspheres was examined (Table  III, A),  neither 
epitope was found to be directly involved in binding. Simi- 
larly, the absence of chondroitin sulfate or HNK-1 epitopes 
from cytotactin did not affect its ability to bind to fibroblasts 
(Table  III,  B).  To confirm that the adhesive activities of 
Covaspheres coated with chondroitinase-treated cytotactin 
or fibroblast cytotactin were due to the cytotactin and not to 
contaminating molecules, these experiments were repeated 
in the presence of  anti-cytotactin Fab' fragments. In all cases, 
binding was inhibited >90%  (data not shown), indicating 
that cytotactin was the active ligand on these beads. 
Expression of Cytotactin and CTB Proteoglycan 
Polypeptides during Development 
Previous  studies  have  indicated that the contributions of 
CAMs and substrate adhesion molecules to cell adhesion are 
dependent both on their absolute local concentrations (19, 
Table IlL Binding Properties of Cytotactin and 
CTB Proteoglycan  Lacking Certain Oligosaccharides 
A. Covasphere-Covasphere  aggregation 
Cytotactin-coated  Ligand on  Superthreshold 
Covaspheres*  Covaspheres*  particlesr 
Control cytotactin  Control proteoglycan  18,600 
Cytotactin w/o CS  Control proteoglycan  12,900 
Cytotactin w/o HNK- 1  Control proteoglycan  17,100 
Control cytotactin  Proteoglycan w/o CS  26,400 
Control cytotactin  Fibronectin  15,300 
Cytotactin w/o CS  Fibronectin  11,500 
Cytotactin w/o HNK-1  Fibronectin  13,400 
B. Covasphere to fibroblast binding 
Protein on 
Covaspheres*  Bound cpmw 
Control cytotactin  2,420 
Cytotactin w/o CS  2,300 
Cytotactin w/o HNK-1  2,280 
Binding assays were performed as described in the Materials and Methods and 
legends of Tables  I and II. 
* Control  cytotactin is cytotactin purified from brain extracts, cytotactin w/o 
CS is cytotactin purified from brain extracts with chondroitin sulfate removed 
by chondroitinase treatment after purification,  cytotactin w/o HNK-1 is cyto- 
tactin purified from fibroblast culture medium and therefore lacking the HNK-1 
carbohydrate  epitope, control proteoglycan  is CTB proteoglycan, and pro- 
teoglycan  w/o CS is CTB proteoglycan  with chondroitin  sulfate removed by 
chondroitinase  treatment. 
Average of duplicate  samples.  SD  in all  cases is <1,500  superthreshold 
particles. 
w  Average of duplicate  samples.  SD in all cases is <200 cpm. 
Hoffman et aL Modulation of Cytotactin and CTB Proteoglycan  523 Figure  2.  Electron micrograph of selected hexabrachions from 
purified cytotactin. Samples were sprayed onto mica,  vacuum- 
dried, and rotary-shadowed  (14). This photograph was taken by Dr. 
Harold P. Erickson, Duke University. Bar, 100 nm. 
20) and on their concentrations relative to other adhesive 
molecules present (21). Because CTB proteoglycan binds to 
cytotactin and thereby inhibits its ability to bind to cells (20), 
it  was  particularly  important  to  determine  the  relative 
amounts and sites of expression of these molecules during 
development. 
Cytotactin and CTB proteoglycan were routinely prepared 
in these studies from the soluble supernatant obtained by 
centrifugation of 14-d-old embryonic chicken brains homog- 
enized in an isotonic detergent-free buffer. To confirm that 
most of the cytotactin and CTB proteoglycan was present in 
this fraction and not in the complementary membrane frac- 
tion, aliquots representing an equal percentage of each frac- 
tion were immunoblotted with anti-cytotactin and anti-CTB 
proteoglycan antibodies and the binding quantitated. Most of 
the cytotactin (74%)  and almost all the CTB proteoglycan 
(94 %) were found in the supernatant fraction; the rest of the 
cytotactin and CTB proteoglycan was recovered in the mem- 
brane  fraction,  and  their molecular  forms  were  indistin- 
guishable from those found in the supernatant. 
To evaluate the levels and molecular forms of  cytotactin  ex- 
pressed in the developing brain, PBS extracts from several 
growth stages  ranging from 6-d-old embryo to adult were 
prepared and immunoblotted with anti-cytotactin antibodies 
(Fig. 3).  Sample loadings were normalized on the basis of 
tissue volume, and each sample was analyzed both with and 
without chondroitinase treatment. Cytotactin was present at 
all stages examined; the highest levels were observed in 6- to 
12-d-old embryos and the lowest in hatchlings and adults. 
Quantitation of these immunoblots indicated that the levels 
of  cytotactin  in extracts from 18-d-old brains and adult brains 
were respectively only 25 and 15 % of the level found in ex- 
tracts  from 6-d-old  brains.  The  Mr  220,000  and  200,000 
components of cytotactin were present at similar levels  in 
6- and 9-d-old embryos, but by 18 d, the Mr 220,000  com- 
ponent was predominant. The chondroitinase-sensitive Mr 
250,000  component was particularly prominent in extracts 
from 9-,  12-,  and 15-d-old brains. 
In previous studies on cytotactin (17) and the J1 antigen 
(24),  polyclonal  antibodies  that  recognized  Mr  220,000 
polypeptides in embryonic brain extracts were also reported 
to recognize Mr  180,000 and  160,000 polypeptides in adult 
brain extracts. A  one-dimensional peptide analysis (17) of 
these M,  180,000 and 160,000 polypeptides suggested, how- 
ever, that they were structurally related to each other but not 
to the Mr 220,000  protein (cytotactin). The highly specific 
anti-cytotactin antibodies and anti-CTB proteoglycan anti- 
bodies used in the present study did not recognize these Mr 
180,000 and  160,000 polypeptides even though they were 
readily detectible in the adult extract using a previously de- 
scribed anti-cytotactin antibody (Fig. 3, lane 15). Moreover, 
a polyclonal antibody was prepared against the purified Mr 
180,000 polypeptide (Fig. 4, lane 1), and this antibody did 
not recognize purified cytotactin (lane 2) even though it de- 
tected  the  Mr  180,000 and  160,000 polypeptides  in  em- 
bryonic extracts (lane 3) and at significantly higher levels in 
hatchling extracts (lane 4).  These results strongly suggest 
that the adult Mr 180,000 and 160,000 polypeptides and the 
embryonic Mr  220,000  and 200,000  polypeptides are  not 
structural variants of the same molecule as has been sug- 
gested in studies of  the so-called J1 antigen (24). On the other 
hand, the myotendinous antigen (4), or tenascin (5), appears 
Figure 3. Developmental  expression of cytotactin in brain extracts. 
PBS extracts of  6-, 9-, 12-, 15-, 18-d-old  embryonic,  hatchling,  and 
adult brain tissue were prepared and chondroitinase treated as de- 
scribed in the Materials and Methods. 25-gl aliquots were resolved 
on SDS gels containing 6% acrylamide. Lanes 1, 3, 5, 7, 9,//, and 
13, untreated extracts from the stages described above; lanes 2, 4, 
6, 8, 10, 12, and 14, chondroitinase-treated  extracts from the stages 
described above; and lane 15, adult extract. The detection methods 
used were immunoblotting  with a_nti-cytotactin  antibodies  prepared 
against the highly purified molecule (lanes 1-14) and immunoblot- 
ting with the previously described (17) anti-cytotactin antibodies 
(lane 15). The migration and Mr  x  10  -3 of standard proteins are 
indicated. 
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denced by our observations that both monoclonal and poly- 
clonal  antibodies  to  the  myotendinous  antigen  recognize 
purified cytotactin (data not shown). 
In contrast to the ready detectability of  cytotactin, the reac- 
tivity  with  the  anti-CTB  proteoglycan antibody  required 
prior treatment of extracts with chondroitinase (Fig. 5). Lev- 
els of CTB proteoglycan expression in the brain increased 
ninefold from 6-d-old embryos to 18-d-old embryos and de- 
creased only ',~25 % between 18-d-old  and adult tissue. Al- 
though the anti-CrB  proteoglycan antibody was prepared 
against  Mr  280,000  material  (see  Fig.  1,  lane  3),  it also 
reacted with molecules of lower molecular weight in chon- 
droitinase-treated extracts.  From 6-d-old embryos to  15-d- 
old embryos, the Mr 280,000 component was predominant; 
however, components of Mr 220,000 and  150,000 were also 
present and became an increasing fraction of the total as de- 
velopment progressed. At later times, as many as eight com- 
ponents ranging from Mr 110,000 to 280,000 were apparent, 
and the components were similar to those observed upon 
storage of purified intact CTB proteoglycan. Whether this 
differential degradation  or  processing  has  functional  sig- 
nificance remains to be determined. 
Cytotactin and  proteoglycan are  readily extracted from 
neural  tissues  in  nondissociative  buffers  (see  above).  In 
previous studies (8), however, it was found that harsher treat- 
ments were required to extract cytotactin from non-neural 
tissues.  To evaluate the conditions under which CTB pro- 
teoglycan is extracted from non-neural tissues, anti-proteo- 
glycan antibodies were used to immunoblot sequential ex- 
tracts of embryonic chicken gizzards, hearts, and fibroblasts 
prepared using PBS, an NP-40-containing buffer, and 8 M 
guanidine-HCl. Unlike cytotactin, in all cases proteoglycan 
was found primarily in the PBS extract and required prior 
chondroitinase treatment for detection (data not shown). 
Histological Distribution of Cytotactin and 
CTB Proteoglycan in Neural 1Issue 
The microscopic distribution of cytotactin and CTB proteo- 
glycan in the brain was examined by immunohistochemistry 
using the cerebellum as an example (Fig. 6). In 15-d-old em- 
bryos, cytotactin was  seen in the intermediate layer and on 
Figure 4. Characterization of anti- 
Mr  180,000 polypeptide  antibod- 
ies.  The Mr  180,000 polypeptide, 
cytotactin,  and  PBS  extracts  of 
brain tissue were prepared as de- 
scribed in the Materials and Meth- 
ods and resolved on SDS gels con- 
raining 6% acrylamide. Lane 1, 2 
~tg Mr  180,000 polypeptide;  lane 
2, 2 I~g cytotactin; lane 3, 25 ktl 18- 
d-old embryonic brain extract; and 
lane 4, 25  ~tl hatchling brain ex- 
tract.  The detection method used 
was  immunoblotting  with  anti- 
Mr 180,000 polypeptide antibodies. 
The migration and Mr  x  10  -3 of 
standard proteins are indicated. 
Figure 5. Developmental expression of CTB proteoglycan in brain 
extracts. PBS extracts of 6-,  9-,  12-, 15-, 18-d-old embryonic, 
hatchling and adult brain tissue were prepared and chondroitinase- 
treated as described in the Materials and Methods. 25-~tl aliquots 
were resolved on SDS gels containing 6% acrylamide. Lanes 1, 3, 
5,  7,  9,  11, and 13, untreated extracts from the stages described 
above; and lanes 2, 4, 6, 8, 10, 12, and 14, chondroitinase-treated 
extracts from the stages described above. The detection method 
used was immunoblotting with anti-CTB proteoglycan antibodies. 
The migration and Mr  x  10  -3 of standard.proteins are indicated. 
developing Bergmann glial fibers as previously described (7, 
8, 17). At this stage, staining with anti-CTB proteoglycan an- 
tibodies  was  very weak in  the  absence of chondroitinase 
treatment. After chondroitinase treatment, however, the dis- 
tribution of CTB proteoglycan was quite similar to that of 
cytotactin, consistent with the possibility of a  role for this 
neuronal molecule in the interactions of neurons migrating 
on Bergmann glia (7). Both molecules remained in the mo- 
lecular layer of the adult cerebellum. 
Previous immunofluorescent staining  experiments using 
neurons and glia in culture indicated that, in the central ner- 
vous system, cytotactin is specifically synthesized by glial 
cells and is found both in an extracellular fibrillar pattern and 
a punctate, perinuclear pattern (17). To evaluate the site of 
synthesis of CTB proteoglycan, cells from 9-d-old embry- 
onic chicken brains were cultured and immunofluorescently 
labeled with anti-CTB proteoglycan antibodies. In double- 
label experiments (Fig. 7), cells with neuronal morphology 
were found to be labeled by both polyclonal anti-CTB pro- 
teoglycan antibodies  and  monoclonal anti-Ng-CAM  anti- 
bodies, which are specific for neurons in the central nervous 
system (10, 18,  35).  Proteoglycan staining occurred in two 
distinct patterns, either in a punctate, perinuclear pattern (B) 
or associated with the cell surface of cell bodies and neurites 
(E). Chondroitinase pretreatment was required for optimal 
levels of anti-CTB proteoglycan staining, and permeabiliza- 
tion was  required to observe the perinuclear staining.  No 
staining of flat cells (presumably glia) was detected with the 
Hoffman et al. Modulation of Cytotactin and CTB Proteoglycan  525 Figure 6. Distribution of cytotactin and CTB-proteoglycan in embryonic and adult cerebellum. In D-d-old embryos, cytotactin staining 
is prominent in the intermediate layer and along the Bergmann glia (A). CTB-proteoglycan  shows  a similar distribution in chondroitinase- 
treated sections and, in addition, is found in the meninges (B). In adult cerebellum, both cytotactin (C) and CTB-proteoglycan (D) are 
strongly  expressed  along the fibers of  the molecular layer. Arrows  in A-D point to the pial surface;  p denotes Purkinje cell layer.  Bar, 100 Ilm. 
anti-CTB proteoglycan or anti-Ng-CAM antibodies. Thus, 
although cytotactin and CFB proteoglycan were co-localized 
in tissue sections (Fig. 6), the data are consistent with the 
previous conclusion that they are specifically synthesized by 
different cell types: CTB proteoglycan by neurons (20) and 
cytotactin by glia (17). 
Localization  of  Cytotactin and CTB Proteoglycan 
in Particular Non-neural Tissues 
To evaluate the extent of  colocalization of  cytotactin  and C~B 
proteoglycan in non-neural tissues, sections of embryonic 
chicken gizzard (Fig. 8), heart (Fig. 9), and cartilage (Fig. 
10) were immunofluorescently labeled with anti-cytotactin 
and anti-CTB proteoglycan antibodies. In the gizzard (Fig. 
8), cytotactin  was present at high levels in the smooth muscle 
(8)  and at low levels in the myenteric ganglia.  Similarly, 
anti-C~B proteoglycan reactivity was observed after chon- 
droitinase treatment in both the smooth muscle and the gan- 
glia.  No  staining for CTB proteoglycan was  observed  in 
these areas in the absence of chondroitinase treatment (not 
shown).  Both  anti-cytotactin and  anti-CTB proteoglycan 
also stained vascular smooth muscle (Fig. 9, A and B). In 
contrast, anti-proteoglycan staining was strong in cardiac 
muscle (Fig. 9 D) in which cytotactin staining was weak or 
absent (Fig. 9  C). 
An interesting pattern of expression of cytotactin and CTB 
proteoglycan was observed in cartilage. We previously found 
strong cytotactin staining in immature chondrocytes (8) and 
in the perichondrium of mature cartilage. As chondrocytes 
differentiated, the most mature central cells lost cytotactin 
while the most peripheral newly formed chondroblasts con- 
tinued to express the molecule, predominantly in a pericellu- 
lar pattern (Fig.  10 A). In chondroitinase-treated sections, 
however, while cytotactin staining was still limited to the area 
of immature cells, the staining appeared to be more exten- 
sive, surrounding cells and completely filling the extracellu- 
lar spaces (Fig. 10 B). When anti-CTB proteoglycan staining 
was examined, a few relatively peripheral cells were found 
to be stained in the absence of chondroitinase treatment (Fig. 
10 C). After such treatment, however, all cells, mature and 
immature,  stained  for  proteoglycan and  the  extracellular 
space appeared to be filled with positive-staining material 
~ig.  10 D).  Clearly, the presence of chondroitin sulfate 
chains can inhibit antibody interactions with these molecules 
as present in tissue sections. 
Differential  Glycosylation of  Molecules Isolated 
from Neural Versus Non-neural Sources 
Cytotactin and CI'B proteoglycan isolated from embryonic 
chicken brain were previously shown to contain carbohy- 
drate epitopes recognized by the HNK-1 monoclonal anti- 
body (17, 20). Other molecules bearing this epitope include 
The Journal of Cell Biology, Volume  106, 1988  526 Figure 7. Immunofluorescent localization of CTB proteoglycan and Ng-CAM. Brain cells from 9-d-old embryonic chickens were cultured 
and double-labeled  using polyclonal anti-CTB proteoglycan antibodies and monoclonal anti-Ng-CAM antibodies and the appropriate sec- 
ond antibodies as described in the Materials and Methods. A--C and D-F each represent a  single field. Note that CTB proteoglycan is 
present either in an intracellular perinuclear pattern (B, arrows) or associated with the cell surface of cell bodies and neurites (E) in the 
same cells that express Ng-CAM (C and F), a neuronal marker. By comparison with phase micrographs of the same fields (,4 and D), 
it is clear that large, flat glial cells (arrowheads)  do not express either CTB proteoglycan or Ng-CAM. Bar,  10 lim. 
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CTB  proteoglycan in  ll-d-old  embryonic 
gizzard. Both cytotactin (.4, C)  and pro- 
teoglycan (B, D) are found in the enteric 
ganglia (g) and at high levels in the smooth 
muscle (m) (A, B). In addition, both mole- 
cules are  prominent  components of the 
large tendinous structures (t) bounding the 
gizzard muscle (C, D). Bar, 100 I.tm. 
N-CAM (18), Ng-CAM (18), myelin-associated glycoprotein 
(27),  and a glycolipid (6).  It is striking that N-CAM from 
non-neural tissues does not express the HNK-1 epitope (30). 
Moreover, a number of  tissues that express N-CAM, cytotac- 
tin, or CTB proteoglycan, for example, heart, smooth mus- 
cle, cartilage, and cultured fibroblasts, do not express the 
HNK-1  epitope as detected histologically (34,  35;  unpub- 
lished observations). To evaluate biochemically whether cy- 
totactin and CTB proteoglycan from one of these sources ex- 
press the HNK-1 epitope, cytotactin and CTB proteoglycan 
purified from brain or from the culture supernatant of chick 
embryo fibroblasts were immunoblotted with HNK-1,  and 
these immunoblots were compared to immunoblots of the 
same samples performed with rabbit antibodies to cytotactin 
and CTB proteoglycan. For both molecules, material from 
the brain was strongly recognized by both the specific rabbit 
antibody and HNK-1 (Fig. 11, compare lane 1 with lane 5 and 
lane 3 with lane 7).  In contrast, material from fibroblasts 
was not recognized by HNK-1  although it was readily de- 
tected with the rabbit antibodies (compare lane 6 with lane 
2 and lane 8 with lane 4). The results indicate that, in certain 
tissues, cytotactin and proteoglycan are expressed without 
the HNK-1 carbohydrate epitope. Nevertheless, the absence 
of the HNK-1 epitope from cytotactin does not alter its three- 
dimensional structure (compare Fig.  2  with references  13 
and 38)  or its binding functions (Table III). 
Discussion 
Here,  we have analyzed various aspects of the  structure, 
binding functions, expression, and distribution of cytotactin 
and CrB proteoglycan. Several of  the results obtained appear 
directly relevant to understanding how these molecules may 
be involved in the differential control of  cell behavior as parts 
of a network of interactive extracellular matrix components 
whose abilities to bind to cells are modulated by their inter- 
molecular interactions.  For example,  both  cytotactin and 
CTB proteoglycan inhibited the binding of either cytotactin 
or fibronectin to cells. The observed alterations in the rela- 
tive expression of cytotactin and CTB proteoglycan during 
brain development may,  through these means,  have func- 
tional effects on neuron-glia adhesion (17) and cerebellar cell 
migration on Bergmann glia, a  process  shown to be per- 
turbed by antibodies to cytotactin (7). 
These observations make clear the need for careful charac- 
terization of these molecules and their properties. In previ- 
ous studies, antibodies to cytotactin (18) and antibodies to J1 
antigen  (24)  were  reported  to  recognize Mr  220,000  and 
200,000  polypeptides in embryonic brain extracts and Mr 
180,000 and 160,000 polypeptides in adult brain extracts, all 
of which contained the carbohydrate epitope recognized by 
monoclonal antibody HNK-1.  Although these "embryonic" 
and "adult" polypeptides have distinct one-dimensional pep- 
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glycan expression in  M-d-old vascular 
smooth muscle and cardiac muscle. Cy- 
totactin staining (A) is found in moderate 
amounts in vascular smooth muscle of 
the great vessels of the heart and is most 
intense between the outermost layers of 
smooth muscle  fibers. CrB-proteogly- 
can (B) is present throughout the layers 
of muscle, although in a concentric, ap- 
parently cell-associated, pattern. In con- 
trast,  no cytotactin can be seen in car- 
diac  muscle  (C),  whereas  this  tissue 
expresses large amounts of CTB proteo- 
glycan (D). Bar,  100 ~tm. 
tide maps (18), it was suggested that, similar to N-CAM (31), 
the J1 antigen had structurally related embryonic and adult 
forms (24).  The present results indicate, however, that the 
Mr  180,000  and  160,000 polypeptides and  the Mr  220,000 
and 200,000 polypeptides are unrelated. Antibodies to highly 
purified  cytotactin do  not  recognize the  Mr  180,000  and 
160,000  polypeptides,  and  antibodies  to  the  Mr  180,000 
polypeptide do not recognize cytotactin. Furthermore, the 
Mr  180,000  and  160,000 polypeptides are  present  in  em- 
bryonic brain extracts and are not strictly adult proteins al- 
though they do continue to increase in concentration during 
later development. It remains to be determined whether the 
Mr  180,000 and 160,000 molecules are involved in neuron- 
glia adhesion or cerebeUar cell migration. It is clear, how- 
ever, that cytotactin is  involved in both processes because 
monoclonal antibodies specific for cytotactin inhibit neuron- 
glia adhesion (17) and cerebeUar cell migration (7). It will 
also be of interest to examine whether these molecules inter- 
act with cytotactin, providing a basis for their copurification 
in earlier studies. 
Two  molecules  described  by  other  investigators,  hexa- 
brachion (13) and myotendinous antigen (4), also known as 
tenascin  (5),  appear  to  be  closely related or  identical to 
cytotactin. All three molecules migrate as Mr 220,000 and 
200,000 polypeptides on SDS gels, and we found that mono- 
clonal and polyclonal anti-myotendinous antigen antibodies 
recognize purified cytotactin. Hexabrachion and tenascin as 
currently purified probably represent subsets of cytotactin 
because  they  are  obtained  from  non-neural  sources  and 
therefore lack the HNK-1 carbohydrate epitope. Neverthe- 
less,  hexabrachion  (13),  myotendinous  antigen  (38),  and 
brain cytotactin all appear as similar six-armed figures (see 
Fig.  2) when analyzed by electron microscopy, suggesting 
that  the  presence of the  HNK-1  carbohydrate epitope on 
cytotactin does not alter its three-dimensional structure. 
A wide range of experiments was performed to character- 
ize further the binding of cytotactin to CTB proteoglycan, 
fibronectin, and cells, all of which were found to be divalent 
cation-dependent. In contrast to fibronectin binding, RGD- 
containing peptides did not inhibit the binding of cytotactin- 
coated beads  to cells.  Nevertheless,  RGD-containing pep- 
tides  do  inhibit  the  binding  of cells  to  cytotactin-coated 
Hoffman et al. Modulation of Cytotactin and CTB Proteoglycan  529 Figure 10. Distribution of cytotactin and CrB- 
proteoglycan in developing cartilage. Sections 
of 14-d-old  embryo sternal cartilage were pro- 
cessed for immunohistology either without (,4, 
C) or with (B, D) chondroitin ABC lyase treat- 
ment and stained with antibodies to either cyto- 
tactin  (A,  B) or CTB proteoglycan (C,  D). 
Cytotactin is present only in immature chon- 
drocytes near the periphery of the tissue (A), 
where proteoglycan  can be observed even with- 
out chondroitinase treatment  (C).  Note that 
the staining for both molecules increases upon 
chondroitinase treatment; cytotactin staining is 
more extensive in extracellular spaces of im- 
mature chondrocytes (B), whereas CTB pro- 
teoglycan is found surrounding all the cells and 
filling  their  extracellular  spaces  (D).  Bar, 
100 I.tm. 
culture dishes (Friedlander, D. R., S. Hoffman, and G. M. 
Edelman, manuscript in preparation), and analysis of cyto- 
tactin cDNA indicates the molecule contains an RGD se- 
quence (22a). These results are consistent with the possibil- 
ity that cytotactin binds to cells via both an RGD sequence 
and a distinct sequence that remains functional in the pres- 
ence of RGD-containing peptides in the Covasphere assay. 
Both cytotactin and proteoglycan appear to exist in multi- 
ple polypeptide forms. Although the particular functions of 
these different forms remain to be established, preliminary 
results suggest that multiple mRNAs exist for cytotactin and 
are differentially distributed in neural and non-neural tissues 
(22a). Thus, it is possible that the various cytotactin polypep- 
tides within neural and non-neural tissues may include differ- 
ent functional domains, as have been demonstrated for other 
extracellular matrix proteins (36,  39). 
In this study, forms of cytotactin and CrB proteoglycan 
were found that possessed or lacked the carbohydrate epi- 
tope recognized by monoclonal antibody HNK-1. Neither the 
HNK-1  carbohydrate nor the chondroitin sulfate found on 
forms of both molecules appears to be directly involved in 
their binding functions, however. Contrary to the suggestion 
that the HNK-1 epitope may act as a ligand in cell-cell bind- 
ing (23), cytotactin lacking this carbohydrate isolated from 
fibroblasts bound as well to CTB proteoglycan, fibronectin, 
and fibroblasts, as did the cytotactin bearing this carbohy- 
drate that was  isolated from brain.  Similarly, chondroitin 
sulfate does not appear to be a ligand in the binding interac- 
tions studied here; specific enzymatic removal of this gly- 
cosaminoglycan had little effect on the binding properties of 
cytotactin and proteoglycan. In  fact,  chondroitinase treat- 
ment of CTB proteoglycan enhanced its ability to bind to 
cytotactin; this may reflect an exposure of binding sites or an 
enhanced coupling of CTB proteoglycan to carrier beads in 
the absence of chondroitin sulfate chains. 
Even though cytotactin and CTB proteoglycan constitute 
The Journal of Cell Biology, Volume  106, 1988  530 F~gure 11. Immunological comparison of cytotactin and CrB pro- 
teoglycan purified  from  brain  and  fibrobtasts. Cytotactin and 
chondroitinase-treated  CTB proteoglycan  were purified from brain 
extracts or fibroblast culture medium as described in the Materials 
and Methods and resolved on SDS gels containing 6% acrylamide. 
Lanes 1 and 5, 2 Bg cytotactin from brain; lanes 2 and 6, cytotactin 
purified from 1 ml fibroblast culture medium; lanes 3 and 7, 2 ~g 
chondroitinase-treated CTB proteoglycan from brain; and lanes 4 
and 8, chondroitinase-treated  CTB proteoglycan  purified from 1 ml 
fibroblast culture medium. The detection methods used were im- 
munoblotting with  anti-cytotactin  antibodies (lanes  1  and  2), 
anti-CI'B proteoglycan  antibodies (lanes 3 and 4), and monoclonal 
antibody HNK-I (lanes 5-8).  The migration and M~  x  10  -3 of 
standard proteins are indicated. 
a binding couple, immunofluorescence localization experi- 
ments indicated that, in certain tissues, the distribution of 
cytotactin and its ligand,  CrB  proteoglycan, are  similar, 
whereas in other tissues they are quite different. Similar dis- 
tributions for the two molecules were observed in the cere- 
bellum, although cell culture experiments indicate that cyto- 
tactin is specifically synthesized by and expressed on gila 
(18), whereas CTB proteoglycan is specifically synthesized 
by and expressed on neurons. Other cells, for example, fi- 
broblasts, were able to synthesize both molecules. Both mol- 
ecules were colocalized in gizzard and vascular smooth mus- 
cle. In contrast, whereas CTB proteoglycan was prominent 
in cardiac muscle and throughout developing cartilage, little 
or no cytotactin was found in cardiac muscle and, in carti- 
lage, it was restricted to immature chondrocytes. These re- 
sults appear to reflect differential site-related synthesis of 
these proteins and they raise the possibility that additional 
ligands for CrB proteoglycan exist in regions where the pro- 
teoglycan is present and cytotactin  is absent. A more detailed 
study of the localization of these molecules in the histogene- 
sis of other organs is likely to reveal correlations with pat- 
terns of morphogenesis, as already seen for neural crest de- 
velopment (34). 
In  the  current  study,  we  have  identified a  variety  of 
parameters that may affect the function of the cytotactin- 
CTB proteoglycan binding couple including developmental 
alterations in their molecular forms and distributions. In ad- 
dition, we have further characterized their molecular binding 
mechanisms. The data raise new questions about the func- 
tional role of the M~ 160,000 and 180,000 proteins and sug- 
gest experiments to explore the site-restricted regulation of 
cytotactin and CTB proteoglycan in development. The com- 
bined results on structure, binding function, and distribution 
of this binding couple, together with the results of earlier 
studies (20), are in accord with the hypothesis that the modu- 
lation of an interactive network of extracellular proteins may 
be an important factor in the control of cellular patterning 
in morphogenesis. 
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